A Double-blind, Placebo- and Active-Controlled Evaluation of the Safety and Efficacy of Levomilnacipran ER in Adolescent Patients With Major Depressive Disorder
Phase of Trial: Phase III
Latest Information Update: 05 Apr 2018
At a glance
- Drugs Levomilnacipran (Primary) ; Fluoxetine
- Indications Major depressive disorder
- Focus Registrational; Therapeutic Use
- Sponsors Allergan; Forest Laboratories
- 20 Nov 2017 Planned End Date changed from 6 Mar 2018 to 21 Dec 2018.
- 20 Nov 2017 Planned primary completion date changed from 6 Mar 2018 to 21 Dec 2018.
- 06 Aug 2017 Planned End Date changed from 21 Dec 2018 to 6 Mar 2018.